Phase 1

Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
(SignalChem) SLC-391-101A Phase 1, Open-label, Dose-escalation, and Dose-expansion Study of the Safety and Pharmacokinetics of the AXL Inhibitor SLC-391 Administered Orally to Subjects with Solid TumoursHotte, Dr SebastienOpen to recruitmentNCT03990454
(Alkermes) ALK4230-A101 / ARTISTRYA Phase 1 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid TumorsHirte, Dr HalRecruitment on hold - COVID-19NCT02799095
(BMS) CA209848 / CheckMate 848A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or
Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High
Tumor Mutational Burden (TMB-H)
Hotte, Dr SebastienSuspended/On holdNCT03668119
(Fusion) FPX-01-01A Phase 1 Study of [225Ac]-FPI-1434 Injection in Patients with Advanced Solid TumoursJuergens, Dr RosalynSuspended/On holdNCT03746431
(Merck) MK-4830-001A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-4830 as Monotherapy and in Combination with Pembrolizumab for Participants with Advanced Solid TumorsHotte, Dr SebastienSuspended/On holdNCT03564691
Download PDF